ArticlePharmacoEconomics - open2025

Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data.

Alison D Griffiths et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.